Search PubMed⌕ Search

Biomedical subjects

S Inaba

Publications and source records attributed to S Inaba.

At least 181 records · Page 10Linked to original sources
PubMed1984

Villous tumor of the stomach associated with adenocarcinomas--a histochemical study of mucosubstances.

A case is described in which both a moderately elevated villous adenoma associated with adenocarcinoma at the posterior wall and an independent gastric carcinoma at the anterior wall were present. These two lesions were surrounded by the mucosa of incomplete intestinal metaplasia. Consecutive sections of the villous adenoma associated focally with carcinoma and the independent cancer were stained by the periodic acid-Schiff (PAS), pH 2.5 alcian blue (A1-B1), high iron diamine pH 2.5 alcian blue (HID-AB) and carcinoembryonic antigen peroxidase-antiperoxidase (CEA-PAP) methods. Villous adenoma was weakly positive in the PAS stain but negative in A1-B1 and HID stains, showing that it did not produce mucin. On the other hand, the intestinal metaplasia and cancerous lesions were positive in PAS, A1-B1 and HID stains, indicating production of the intestinal type of mucin. The villous adenoma accompanied by malignant changes was positive by the CEA-PAP method. This result shows the biological property of villous adenoma that they can easily change into malignancy. These three lesions in our case are considered to have originated independently from the primordial cells and to have developed the differences in mucin production in the process of cell development.

Adenocarcinoma↗
PubMed1983

The effect of immunotherapy with extracted tumor antigens on sinecomitant immunity.

The fate of hosts after tumor resection depends upon the level of their sinecomitant immunity, which can destroy residual neoplastic cells. In addition, active specific immunotherapy can stimulate the resistance of mice incompletely resected of large tumors and therefore destined to develop recurrent disease. The studies presented herein, assessing host resistance by in vivo tumor challenge and an in vitro growth inhibition assay (GIA) measuring the effect of splenic lymphocytes on 3H-thymidine incorporation into monolayers of sarcoma cells, revealed an antagonistic relationship between sinecomitant immunity and tumor antigen immunotherapy. Treatment of hosts bearing high levels of endogenous sinecomitant immunity with Fraction 15 pI 5.95 partially purified from 3 M KCl extracts by preparative isoelectric focusing, decreased their resistance to tumor challenge and the capacity of their spleen cells to perform in the in vitro GIA. When sinecomitant immunity was not demonstrable, therapy with tumor antigen induced host resistance. If therapy was delayed until sinecomitant immunity had naturally waned, hosts displayed improved resistance toward secondary challenge. These findings suggest that not only does antigen therapy effect tumor resistance by a mechanism independent of sinecomitant immunity, but also these two mechanisms are mutually antagonistic. Therefore, the design of active specific immunotherapy protocols utilizing tumor antigens may depend on the level of the host endogenous sinecomitant resistance.

Animals↗
PubMed1983

[Mucohistochemical studies of CEA producing and non-producing stomach cancers].

In this report, 141 patients with gastric cancer were studied histochemically. Tissue CEA was stained by the CEA-PAP method and the gastric cancer was classified into CEA-producing (96 cases, 68.1%) and CEA non-producing gastric cancer (45 cases, 31.9%). Histologically, CEA-producing gastric cancer was well differentiated adenocarcinoma and CEA non-producing gastric cancer was chiefly undifferentiated carcinoma. PAS, pH 2.5 Alcian-blue, High Iron Diamine, Alkaline-PAS, and Concanavalin A paradoxical stain were applied to specimens from each type of gastric carcinoma. Mucosubstances of CEA-producing gastric cancer were positive for A-B, HID, AL-PAS and CPS III-1; those of CEA non-producing gastric cancer were positive for PAS and CPS III-s, but negative for A-B, HID and A1-PAS. These results suggest that CEA-producing gastric cancer arises from intestinal metaplasia of gastric mucosa and that CEA non-producing gastric cancer arises from the gastric mucosa itself.

Adenocarcinoma↗
PubMed1983

[Specific active immunotherapy of murine methylcholanthrene-induced sarcoma using a partially purified soluble tumor specific transplantation antigens].

Immunotherapeutic effects of soluble tumor specific transplantation antigens (TSTA) were studied, Crude 3M KC1 extract of C3H/He methylcholanthrene-induced sarcoma (F tumor) was purified by preparative isoelectric focusing (pIEF). The immunoprotective fraction (Fr. 15, pI 5.7-6.0) possessed about 50 fold greater activity than the crude 3M KC1 extract. Three weekly injections of optimal immunoprotective dose of Fr. 15 retarded the outgrowth of F cells and decreased the outgrowth and tumor incidence of rechallenged inoculation in mice completely resected established 1 cm tumor. Weekly injections of Fr. 15 resulted in decreased local recurrences. This therapeutic effect was immunologically specific. Fr. 15 alone did not show the therapeutic effects on the established tumor, but combined treatment with cyclophosphamide gave the increased survivals. A metastatic variant cell line (F-4) metastasized to the lung spontaneously after the resection of primary subcutaneous tumor. Therapeutic injections of Fr. 15 decreased the rates of spontaneous pulmonary metastasis of F-4. Since cross-immunoprotection tests revealed that F and F-4 share the common TSTA, the therapeutic effect of Fr. 15 upon pulmonary metastases might be due to improved host's specific immunity.

Animals↗